T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx

International Journal of Cancer

Volumn 118, Issue 8, 2006, Pages 1984-1991

  Hoffmann, Thomas K ^a   Arsov, Christian ^a   Schirlau, Kerstin ^a   Bas, Murat ^a   Friebe Hoffmann, Ulrike ^a   Klussmann, Jens Peter ^b   Scheckenbach, Kathrin ^a   Balz, Vera ^a   Bier, Henning ^a   Whiteside, Theresa L ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Head and neck cancer; HPV; Specific T cells; Tetramer

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; PROTEIN E7; PROTEIN P16; RNA DIRECTED DNA POLYMERASE; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FLOW MEASUREMENT; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; MULTICOLOR FLOW ANALYSIS; OROPHARYNX; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

ANTIGENS, VIRAL; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS;

EID: 33645215135     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21565     Document Type: Article

References (37)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
2. Brandsma JL, Abramson AL. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 1989;115:621-5.
3. Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Yokes EE, Weichselbaum RR. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 1996;2:755-62.
4. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 1997;79:595-604.
5. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao EJ, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998;90:1626-36.
6. Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Weidauer H, Bosch FX. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinoma lacking retinoblastoma cell cycle control. Cancer Res 1998;58:5-13.
7. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
8. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000;89:300-4.
9. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125-31.
10. Klussmann JP, Weissenborn S, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister H, Fuchs P. Prevalence, distribution and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001;92:2875-84.
11. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP, Haugen TH. HPV infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336-44.
12. Snijders PJ, Scholes AG, Hart CA, Jones AS, Vaughan ED, Woolgar JA, Meijer CJ, Walboomers JM, Field JK. Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinoma of the head and neck. Int J Cancer 1996;66:464-9.
13. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
14. von Knebel Doeberitz M, Rittmuller C, zur Hausen H, Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 1992;51:831-4.
15. Klussmann JP, Gültekin E, Weissenborn SJ, Wieland U, Dries Vdienes HP, Eckel HE, Pfister HJ, Fuchs PG. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003;162:747-53.
16. Altman JD, Moss PAH, Goulder PR, Barouch DH, McHeyzer-Willians MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
17. Davis MM, Boniface JJ, Reich Z, Lyons DS, Hampl J, Arden B, Chien YH. Ligand recognition by αβ T cell receptors. Annu Rev Immunol 1998;16:523-44.
18. Kast WM, Brandt RMP, Drijfhout JW, Melief CJM. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993;14:115-20.
19. Kast WM, Brandt RMP, Sidney J, Drijfhout JW, Kubo RT, Melief CJM, Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152:3904-12.
20. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartmann M, Oseroff C, Grey HM, Melief CJM, Kast WM. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995;154:5934-43.
21. Alexander M, Salgaller ML, Celis EC, Sette A, Barnes WA, Rosenberg SA, Steller MA. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996;175:1587-93.
22. McNeil C. HPV vaccines for cervical cancer move toward clinic, encounter social issues. J Natl Cancer Inst 1997;89:1664-6.
23. van Driel WJ, Kenter GG, Fleuren GJ, Melief CJ, Trimbos BJ. Immunotherapeutic strategies for cervical squamous carcinoma. Hematol Oncol Clin North Am 1999;13:259-73.
24. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, Sette A, Trimble EL, Park RC, Marincola FM. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4:2103-9.
25. Ressing ME, van Driel WJ, Brandt RMP, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000;23:255-66.
26. Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S. Use of fluorogenic histocompatibility leukocyte antigen-A*201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res 2000;60:365-71.
27. Hoffmann TK, Donnenberg V, Friebe U, Meyer M, Rinaldo CR, DeLeo AB, Whiteside TL, Donnenberg AD. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry 2000;41:321-8.
28. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M. Over-expression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
29. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and down regulated by tumor necrosis factor a. J Exp Med 1994;179:1109-18.
30. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W. The use of HLA-A*0201-transfected K562 as standard antigen presenting cells for CD(+) T lymphocytes in IFN-γ ELISPOT assays. J Immunol Methods 2002;259:95-110.
31. 264-272 peptide in cancer patients-implications for immunoselection of epitope-loss variants. J Immunol 2000:165:5938-44.
32. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406-16.
33. Devaraj K, Gillison ML, Wu TC. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med 2003;14:345-62.
34. Bauer M, Wagner H, Lipford GB. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented. Immunol Lett 2000;71:55-9.
35. Street MD, Doan T, Herd KA, Tindle RW. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology 2002;106:526-36.
36. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, Anholts JD, Schreuder GM, ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 1996;56:582-8.
37. 264-272 peptide in the circulation of patients with head and neck cancer. Cancer Res 2002;62:3521-9.